LINCOLN, Neb. — Celerion announced today the multimillion-dollar expansion of specialized pharmacies across their clinical research units in North America, demonstrating their commitment to further assisting sponsors in meeting the forthcoming USP requirements for compounding investigational drug product in support of early phase clinical trial research.
Celerion’s purpose-built, pharmaceutical compounding facilities include a total of seven highly specialized pharmacy suites where investigational formulations are prepared under USP-compliant conditions, including General Chapters <795>, <797>, and <800>. The facilities feature designated compounding suites equipped with systems controlling negative and positive differential air pressure in ISO classified areas, independent HEPA filtered air ventilation systems and equipment, and preparation viewing areas.